SecurityScorecard Unveils Sophisticated Cyber Intelligence Powering New Solutions to Counter Threat Actors
New Attack Surface Intelligence module and Cyber Risk Intelligence service empower security teams to stay…
New Attack Surface Intelligence module and Cyber Risk Intelligence service empower security teams to stay…
NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) — Better Choice Company Inc. (NYSE American: BTTR)…
NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) — Better Choice Company Inc. (NYSE American: BTTR)…
MELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE,…
MELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE,…
Data Presented at the ACG Annual Meeting Demonstrates Successful Detection of Colon Entry and Topical…
Data Presented at the ACG Annual Meeting Demonstrates Successful Detection of Colon Entry and Topical…
MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ET Company to host “The…
Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ET Company to host “The…
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus…
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus…
Brings deep industry experience spanning financial and operational roles to support Company and its new…
Brings deep industry experience spanning financial and operational roles to support Company and its new…
Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET…
Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET…
Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at…
Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at…
Proteros selected by Adrestia for its cutting-edge structure-based drug discovery engine Proteros to support Adrestia…